Affordable Access

deepdyve-link
Publisher Website

Sialylated IgG-Fc: a novel biomarker of chronic inflammatory demyelinating polyneuropathy.

Authors
  • Wong, Anna Hiu Yi1
  • Fukami, Yuki1
  • Sudo, Makoto1
  • Kokubun, Norito2
  • Hamada, Shinsuke3
  • Yuki, Nobuhiro4
  • 1 Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. , (Singapore)
  • 2 Department of Neurology, Dokkyo Medical University, Tochigi, Japan. , (Japan)
  • 3 Department of Neurology, Hokuyukai Neurological Hospital, Sapporo, Japan. , (Japan)
  • 4 Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. , (Singapore)
Type
Published Article
Journal
Journal of Neurology Neurosurgery & Psychiatry
Publisher
BMJ
Publication Date
Mar 01, 2016
Volume
87
Issue
3
Pages
275–279
Identifiers
DOI: 10.1136/jnnp-2014-309964
PMID: 25814494
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Sialylation in Fc portion of IgG plays a crucial role in the pathogenesis of autoimmune diseases and the working mechanism of intravenous immunoglobulin (IVIG). We aim to test whether IgG-Fc sialylation is a biomarker of disease activity for chronic inflammatory demyelinating polyneuropathy (CIDP). By using specific lectins for sialylation, galactosylation and agalactosylation, lectin-enzyme assay and lectin blotting with pretreatment of IgG degradating enzyme of Streptococcus pyogenes were performed to compare the glycosylation levels of serum IgG-Fc (1) between patients of untreated CIDP (n=107) and normal control subjects (n=27), (2) among patients with untreated CIDP of different clinical severities and (3) before and after IVIG treatment of patients with CIDP (n=12). Sialylation and galactosylation of IgG-Fc were significantly reduced in patients with CIDP than normal control subjects (p=0.003 and 0.033, respectively), whereas agalactosylation was increased in CIDP (p=0.21). Ratios of sialylated/agalactosylated IgG-Fc levels were significantly reduced in CIDP (p<0.001) and inversely related to disease severity (p=0.044). After IVIG treatment, levels of sialylated IgG-Fc significantly increased (p=0.003). Sialylation of IgG-Fc is reduced in CIDP. Its level correlated with clinical severity and increased after IVIG treatment. Sialylated as well as ratio of sialylated/agalactosylated IgG-Fc could be new measures to monitor the disease severity and treatment status in CIDP. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Report this publication

Statistics

Seen <100 times